Emmaus Life Sciences, Inc. (EMMA)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 33.1 Million USD | 31.89% |
| 2022 | 25.09 Million USD | -16.11% |
| 2021 | 29.91 Million USD | 57.56% |
| 2020 | 18.98 Million USD | -2.51% |
| 2019 | 19.47 Million USD | 3194.7% |
| 2018 | 591.1 Thousand USD | 1532.87% |
| 2017 | 36.2 Thousand USD | -61.32% |
| 2016 | 93.6 Thousand USD | -96.62% |
| 2015 | 2.76 Million USD | 86.81% |
| 2014 | 1.48 Million USD | 11125.76% |
| 2013 | 13.2 Thousand USD | -95.46% |
| 2012 | 290.6 Thousand USD | -93.21% |
| 2011 | 4.27 Million USD | 14023.1% |
| 2010 | 30.3 Thousand USD | -76.01% |
| 2009 | 126.3 Thousand USD | -52.3% |
| 2008 | 264.8 Thousand USD | 429.6% |
| 2007 | 50 Thousand USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 106.98 Thousand USD | 18.69% |
| 2004 | 90.13 Thousand USD | 509.03% |
| 2003 | 14.8 Thousand USD | 74.12% |
| 2002 | 8500.00 USD | 37.1% |
| 2001 | 6200.00 USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 31.44 Million USD | -0.95% |
| 2024 Q1 | 31.74 Million USD | -4.11% |
| 2023 Q3 | 35.33 Million USD | -4.19% |
| 2023 FY | 33.1 Million USD | 31.89% |
| 2023 Q1 | 27.17 Million USD | -11.83% |
| 2023 Q2 | 36.88 Million USD | 35.74% |
| 2023 Q4 | 33.1 Million USD | -6.32% |
| 2022 FY | 25.09 Million USD | -16.11% |
| 2022 Q2 | 35.42 Million USD | 22.18% |
| 2022 Q1 | 28.99 Million USD | -3.09% |
| 2022 Q3 | 34.23 Million USD | -3.36% |
| 2022 Q4 | 30.81 Million USD | -9.97% |
| 2021 Q2 | 27.72 Million USD | -7.89% |
| 2021 FY | 29.91 Million USD | 57.56% |
| 2021 Q4 | 29.91 Million USD | 1.14% |
| 2021 Q3 | 29.57 Million USD | 6.7% |
| 2021 Q1 | 30.09 Million USD | 58.51% |
| 2020 Q2 | 20.96 Million USD | 7.93% |
| 2020 FY | 18.98 Million USD | -2.51% |
| 2020 Q1 | 19.42 Million USD | -0.28% |
| 2020 Q4 | 18.98 Million USD | -7.24% |
| 2020 Q3 | 20.47 Million USD | -2.35% |
| 2019 FY | 19.47 Million USD | 3194.7% |
| 2019 Q2 | 618.2 Thousand USD | 1.46% |
| 2019 Q3 | 23.76 Million USD | 3744.23% |
| 2019 Q4 | 19.47 Million USD | -18.05% |
| 2019 Q1 | 609.3 Thousand USD | 1.52% |
| 2018 Q4 | 600.2 Thousand USD | 1.54% |
| 2018 Q3 | 591.1 Thousand USD | 1.53% |
| 2018 Q2 | 582.2 Thousand USD | 0.85% |
| 2018 Q1 | 577.3 Thousand USD | -1.59% |
| 2018 FY | 591.1 Thousand USD | 1532.87% |
| 2017 Q3 | 36.2 Thousand USD | -28.74% |
| 2017 FY | 36.2 Thousand USD | -61.32% |
| 2017 Q4 | 586.6 Thousand USD | 1520.44% |
| 2017 Q2 | 50.8 Thousand USD | -22.21% |
| 2017 Q1 | 65.3 Thousand USD | -17.96% |
| 2016 Q4 | 79.6 Thousand USD | -14.96% |
| 2016 Q1 | 3.97 Million USD | 7.98% |
| 2016 FY | 93.6 Thousand USD | -96.62% |
| 2016 Q2 | 4.58 Million USD | 15.28% |
| 2016 Q3 | 93.6 Thousand USD | -97.96% |
| 2015 Q3 | 2.76 Million USD | 28.03% |
| 2015 FY | 2.76 Million USD | 86.81% |
| 2015 Q4 | 3.67 Million USD | 32.92% |
| 2015 Q2 | 2.16 Million USD | 12.33% |
| 2015 Q1 | 1.92 Million USD | 27.43% |
| 2014 Q2 | 7900.00 USD | -18.56% |
| 2014 Q1 | 9700.00 USD | -15.65% |
| 2014 Q4 | 1.51 Million USD | 1.94% |
| 2014 FY | 1.48 Million USD | 11125.76% |
| 2014 Q3 | 1.48 Million USD | 18656.96% |
| 2013 FY | 13.2 Thousand USD | -95.46% |
| 2013 Q1 | 7.26 Million USD | -22.28% |
| 2013 Q4 | 11.5 Thousand USD | -12.88% |
| 2013 Q3 | 13.2 Thousand USD | -99.8% |
| 2013 Q2 | 6.53 Million USD | -10.04% |
| 2012 FY | 290.6 Thousand USD | -93.21% |
| 2012 Q4 | 9.35 Million USD | 3117.62% |
| 2012 Q3 | 290.6 Thousand USD | -95.76% |
| 2012 Q2 | 6.84 Million USD | 12.99% |
| 2012 Q1 | 6.06 Million USD | 17.31% |
| 2011 Q3 | 4.27 Million USD | 46.78% |
| 2011 Q1 | 1.59 Million USD | 157.12% |
| 2011 FY | 4.27 Million USD | 14023.1% |
| 2011 Q2 | 2.91 Million USD | 82.65% |
| 2011 Q4 | 5.16 Million USD | 20.74% |
| 2010 Q2 | 117.5 Thousand USD | 48.36% |
| 2010 FY | 30.3 Thousand USD | -76.01% |
| 2010 Q4 | 620.8 Thousand USD | 1948.84% |
| 2010 Q1 | 79.2 Thousand USD | -23.03% |
| 2010 Q3 | 30.3 Thousand USD | -74.21% |
| 2009 Q1 | 721.4 Thousand USD | 196.51% |
| 2009 FY | 126.3 Thousand USD | -52.3% |
| 2009 Q4 | 102.9 Thousand USD | -18.53% |
| 2009 Q2 | 988.5 Thousand USD | 37.03% |
| 2009 Q3 | 126.3 Thousand USD | -87.22% |
| 2008 Q2 | 277.7 Thousand USD | 202.84% |
| 2008 Q1 | 91.7 Thousand USD | 83.4% |
| 2008 FY | 264.8 Thousand USD | 429.6% |
| 2008 Q4 | 243.3 Thousand USD | -8.12% |
| 2008 Q3 | 264.8 Thousand USD | -4.65% |
| 2007 Q2 | 50 Thousand USD | 0.0% |
| 2007 Q1 | 50 Thousand USD | -98.4% |
| 2007 FY | 50 Thousand USD | 0.0% |
| 2007 Q4 | 50 Thousand USD | 0.0% |
| 2007 Q3 | 50 Thousand USD | 0.0% |
| 2006 Q1 | 103.6 Thousand USD | -3.16% |
| 2006 Q3 | - USD | -100.0% |
| 2006 Q4 | 3.11 Million USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q2 | 111.42 Thousand USD | 7.55% |
| 2005 Q4 | 106.98 Thousand USD | 3.81% |
| 2005 Q1 | 96.13 Thousand USD | 6.66% |
| 2005 Q2 | 99.33 Thousand USD | 3.33% |
| 2005 FY | 106.98 Thousand USD | 18.69% |
| 2005 Q3 | 103.05 Thousand USD | 3.74% |
| 2004 FY | 90.13 Thousand USD | 509.03% |
| 2004 Q4 | 90.13 Thousand USD | 33.1% |
| 2004 Q2 | 66.94 Thousand USD | 352.34% |
| 2004 Q1 | 14.8 Thousand USD | 0.0% |
| 2004 Q3 | 67.72 Thousand USD | 1.15% |
| 2003 Q1 | 9700.00 USD | 14.12% |
| 2003 Q2 | 13.7 Thousand USD | 41.24% |
| 2003 Q3 | 13.7 Thousand USD | 0.0% |
| 2003 Q4 | 14.8 Thousand USD | 8.03% |
| 2003 FY | 14.8 Thousand USD | 74.12% |
| 2002 Q3 | 8500.00 USD | -15.0% |
| 2002 Q4 | 8500.00 USD | 0.0% |
| 2002 Q2 | 10 Thousand USD | 61.29% |
| 2002 Q1 | 6200.00 USD | 0.0% |
| 2002 FY | 8500.00 USD | 37.1% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | 10 Thousand USD | 0.0% |
| 2001 Q4 | 6200.00 USD | -38.0% |
| 2001 FY | 6200.00 USD | 0.0% |
| 2001 Q3 | 10 Thousand USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1999 Q4 | - USD | -100.0% |
| 1999 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 19.664% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -703.041% |
| SQZ Biotechnologies Company | 27.47 Million USD | -20.494% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 23.683% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -11.2% |
| Mesoblast Limited | 118.7 Million USD | 72.114% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -3390.669% |
| Genus plc | 233.1 Million USD | 85.8% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -1029.577% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2363.635% |
| Marizyme, Inc. | 18.71 Million USD | -76.845% |
| ContraFect Corporation | 2.88 Million USD | -1048.941% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -4313.467% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -24331.126% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -2188.638% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -1323.114% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -484.994% |
| MultiCell Technologies, Inc. | 202.58 USD | -16339617.642% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 42.422% |
| EV Biologics, Inc. | 1.49 Million USD | -2114.483% |
| Q BioMed Inc. | 4.1 Million USD | -705.381% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -5153.485% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -2594.729% |
| Biomind Labs Inc. | 735.54 Thousand USD | -4400.219% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 80.704% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -154.682% |
| Skye Bioscience, Inc. | 4.61 Million USD | -617.207% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -3627.321% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -23289.957% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -463.797% |
| IMV Inc. | 28.88 Million USD | -14.6% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -128602.516% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -1365.696% |
| GB Sciences, Inc. | 1.75 Million USD | -1781.479% |
| Alpha Cognition Inc. | 1.22 Million USD | -2612.37% |
| HST Global, Inc. | 98.31 Thousand USD | -33566.941% |
| CSL Limited | 12.18 Billion USD | 99.728% |
| Halberd Corporation | 150 Thousand USD | -21967.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -3222.266% |
| Resverlogix Corp. | 6.49 Million USD | -409.952% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -6832.147% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -12850.718% |
| argenx SE | 20 Million USD | -65.505% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 27.346% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1122.024% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -323626.161% |
| Genscript Biotech Corporation | 417.73 Million USD | 92.076% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -16399.681% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -1280.518% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -14336.24% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 51.065% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -993.817% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -9102.135% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -62.835% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -22167.144% |
| BioStem Technologies, Inc. | 4.71 Million USD | -602.57% |
| ONE Bio Corp. | 19.71 Million USD | -67.897% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -13130.768% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -13208.54% |
| Agentix Corp. | 50 Thousand USD | -66102.0% |
| LadRx Corporation | 33.6 Thousand USD | -98397.292% |
| Cell Source, Inc. | 9.25 Million USD | -257.687% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -4277.258% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -4277.258% |
| NovAccess Global Inc. | 2.19 Million USD | -1404.673% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -368.004% |
| Itoco Inc. | 228.37 Thousand USD | -14394.016% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -15589.537% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -564.279% |
| Kadimastem Ltd | 891.22 Thousand USD | -3614.097% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -8137.174% |
| CytoDyn Inc. | 30.07 Million USD | -10.058% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -6735.039% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -9307.782% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -323.289% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -26921.224% |
| Rebus Holdings, Inc. | 310 Thousand USD | -10577.742% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -599.029% |
| International Stem Cell Corporation | 4.17 Million USD | -692.269% |
| Bioxytran, Inc. | 1.92 Million USD | -1619.532% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -52935.425% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1417.768% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -298.04% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -285.568% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -2028.026% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -12251.119% |
| Neutra Corp. | 54.15 Thousand USD | -61021.575% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -1708.798% |
| PureTech Health plc | 25.51 Million USD | -29.747% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -2603.831% |
| IXICO plc | 472.02 Thousand USD | -6912.582% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -113.541% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 46.837% |
| CSL Limited | 12.18 Billion USD | 99.728% |
| Cellectis S.A. | 92.77 Million USD | 64.322% |